Shigella dysenteriae Serotype 1, Kolkata, India by Dutta, Shanta et al.
Shigella 
dysenteriae
Serotype 1,
Kolkata, India
Shanta Dutta,* Dharitri Dutta,* Phalguni Dutta,*
Shigeru Matsushita,† Sujit Kumar Bhattacharya,*
and Shin-ichi Yoshida‡
Since July 2002, bacteriologically confirmed shigel-
losis cases have increased, and multidrug-resistant
Shigella dysenteriae serotype 1 strains have reemerged in
patients hospitalized with diarrhea in Kolkata, India. The
isolated strains of S. dysenteriae 1 showed resistance to
chloramphenicol (80%), ampicillin (100%), tetracycline
(100%), co-trimoxazole (100%), nalidixic acid (100%), nor-
floxacin (100%), and ciprofloxacin (100%). Emergence of
fluoroquinolone resistance in S. dysenteriae 1 strains com-
plicated treatment of shigellosis patients. Six strains
belonging to provisional serovars of S. dysenteriae were
also identified for the first time in patients hospitalized with
diarrhea in Kolkata, India.
S
higellosis is an important cause of bloody diarrhea in
all age groups, especially in children. Of all serotypes
of shigellae, Shigella dysenteriae type 1 attracts special
attention for its epidemic-causing potential and its associ-
ation with most serious dysentery cases, with a high attack
rate, high case-fatality rate, and various complications (1).
Antimicrobial therapy is usually recommended for treat-
ment of shigellosis. However, antimicrobial resistance in
enteric pathogens, including Shigella isolates, complicates
the situation in developing countries, where shigellosis is
endemic and indiscriminate use of antimicrobial agents is
common. 
During early 1984, various areas of India, including the
eastern region, witnessed an extensive epidemic of bloody
dysentery, predominantly caused by multidrug-resistant S.
dysenteriae type 1, which swept through the districts of
West Bengal from north to south. The strains were resist-
ant to streptomycin, tetracycline, and chloramphenicol;
highly sensitive to nalidixic acid, gentamicin, furazoli-
done; and moderately sensitive to ampicillin and cotrimox-
azole (2). Nalidixic acid–resistant strains of S. dysenteriae
1 emerged in Eastern India during 1988 (3). In 1992, S.
dysenteriae 1 was isolated from 24% of total bloody diar-
rhea case-patients, and the strain showed resistance to
nalidixic acid (30%), furazolidone (2%), ampicillin (95%),
and co-trimoxazole (88%). All strains were susceptible to
fluoroquinolone derivatives, i.e., norfloxacin and
ciprofloxacin (4). Therefore, furazoldione and nalidixic
acid were used as first-line drugs for shigellosis during that
period, with selective use of fluoroquinolones.
Changes in the worldwide epidemiology of shigellae
species have been documented in the last two decades.
Although bacteriologically confirmed childhood shigellosis
cases varied from 4% to 6%, a change in serotypes and
antimicrobial resistance in Shigella species was noticed in
Kolkata during 1995–2000 (5). S. flexneri (58%) complete-
ly replaced S. dysenteriae (5%) and became the most preva-
lent serotype, followed by S. sonnei (28%) and S. boydii
(9%). During 1997 to 2000, S. dysenteriae type 1 strain was
not isolated. One strain of S. dysenteriae, isolated in 1999,
and three strains of S. dysenteriae, isolated in 2000,
belonged to S. dysenteriae type 2 (unpub. data). Isolated
strains were resistant to nalidixic acid (29% with MIC90
<128 µg/mL), tetracycline (90%), co-trimoxazole (90%),
ampicillin (67%), and chloramphenicol (46%). Again all
strains were susceptible to norfloxacin (MIC90 <1 µg/mL)
and ciprofloxacin (MIC90 = 0.125 µg/mL), rendering them
drugs of choice for treatment of shigellosis in recent years.
Routine surveillance data from National Institute of
Cholera and Enteric Diseases (NICED) showed a 1% to 2%
isolation rate of all Shigella serotypes from diarrhea
patients since 1997, with the identification of a single strain
of S. dysenteriae type 1 in 1998. 
This study, performed as a continuation of routine sur-
veillance for diarrheal diseases in two large hospitals in
Kolkata, found a recent increase in patients seeking treat-
ment for acute and severe bloody diarrhea and the reemer-
gence of S. dysenteriae 1 strains with altered antibiogram. 
The Study
During April–May 2002, an outbreak of bacillary
dysentery was reported in the northern district of West
Bengal, India, among tea garden workers. A team from
National Institute of Cholera and Enteric Diseases inves-
tigated the episode, and S. dysenteriae 1 was found to be
the sole causative agent of the outbreak (6). A similar out-
break of blood dysentery caused by S. dysenteriae 1
occurred during March–June 2002 in the southern part of
West Bengal (7). Following these episodes, we intensified
the surveillance of diarrheal diseases in two hospitals of
Kolkata, India. Infectious Disease (I.D.) Hospital is the
biggest hospital in Kolkata, if not in India, for admission
and treatment of infectious disease cases and the Dr. B. C.
Roy Memorial Children’s Hospital is the only referral
pediatric hospital in the state of West Bengal, which usual-
ly serves an area that includes the Kolkata metropolis and
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*National Institute of Cholera and Enteric Diseases, Kolkata, India;
†Metropolitan Research Laboratory of Public Health, Tokyo,
Japan; and ‡Faculty of Medical Sciences, Kyushu University,
Fukuoka, Japansuburbs. In both hospitals, patients with diarrhea were kept
under continuous surveillance after admission to the
Diarrhoea Treatment Unit (DTU) of the hospitals and were
treated with oral rehydration solution and antimicrobial
agents as advised by attending clinicians. 
Rectal swabs or fresh stool samples were collected
from children with acute diarrhea admitted to Dr. B.C. Roy
Memorial Children’s Hospital, Kolkata from January 2001
through August 2002. The children were selected irrespec-
tive of type, duration of diarrhea, and history of antibiotic
drug therapy.
During the first week of July 2002, an upsurge of acute
bloody diarrhea cases was noticed in patients attending the
I.D. Hospital, Kolkata, and increased numbers of patients
with acute dysentery continued to be admitted to the hos-
pital until September 2002. The patients reported bloody
stools, abdominal pain, and tenesmus, with or without
fever. Stool samples or rectal swabs were collected from
all of these patients on admission from July 1, 2002, to
August 31, 2002.
The samples were placed in Cary-Blair transport medi-
um and processed within 2 hours of collection in the
Microbiology Laboratory of the National Institute of
Cholera and Enteric Diseases, Kolkata; the samples were
tested for the entire gamut of enteropathogens by using
standard techniques. Shigella species were confirmed with
the API 20E test (Biomerieux, Marcy l’Etoile, France) and
slide agglutination test with antisera specific to serotypes
of  Shigella species (Denka Seiken Co, Tokyo, Japan).
Antimicrobial susceptibility testing of Shigella isolates
was done by the disk diffusion method, and MICs were
measured by using the agar dilution method. 
In addition to the conventional technique, polymerase
chain reaction (PCR) was performed within 4–6 hours on
LB broth cultures of 77 stool samples collected from I. D.
Hospital by using published primer sequences for IpaH
(invasion plasmid antigen H) gene to detect further
Shigella infection, which might have been missed by con-
ventional methods (8). PCR was also performed in antici-
pation of rapid diagnosis and early treatment of shigel-
losis cases and thus prevent the development of complica-
tions.
Table 1 shows the distribution of Shigella serotypes
from patients admitted in two hospitals of Kolkata. An
increased isolation rate of all serotypes of shigellae was
observed in patients with acute diarrhea (72/790; 9.1%)
and also in patients with bloody diarrhea (72/237; 30%) in
the Children’s Hospital since January 2002. Although S.
flexneri continued to be the most prevalent serotype
(45/72; 62.5%), followed by S. sonnei (18/72; 25%), the
reemergence of S. dysenteriae serotype 1 (5/72; 7%)
claimed special attention. During 2001, only one strain of
S. dysenteriae 1 was isolated in July, but during January to
August 2002, five S. dysenteriae 1 strains were identified:
one in April and two in both July and August 2002. The
other four S. dysenteriae strains isolated in 2001 were S.
dysenteriae type 2 (two strains), S. dysenteriae type 3 (one
strain), and S. dysenteriae type 6 (one strain). 
Among 77 patients with bloody diarrhea in I. D.
Hospital examined through August 2002, Shigella spp.
were identified as the sole pathogen in 27 (35%) patients.
Of 27 Shigella strains, 24 (88%) belonged to S. dysenteri-
ae serotype 1; other strains isolated were S. flexneri (2
strains) and S. sonnei (1 strain). PCR could detect shigel-
lae infection in 37 (48%) patients, and 12 of these patients
were not culture-positive. No other pathogen could be
detected in samples from any of the case-patients. The
Figure shows the epidemic curve for S. dysenteriae 1 case-
patients admitted to I.D. Hospital during the period of
study.
The antimicrobial resistance profiles of the isolated S.
dysenteriae 1 strains showed multidrug resistance to at
least seven or more antimicrobial agents, e.g., chloram-
phenicol (80%), ampicillin (100%), tetracycline (100%),
cotrimoxazole (100%), furazolidone (50%), nalidixic acid
(100%), ciprofloxacin (100%), norfloxacin (100%), and
amoxicillin (100%). MICs of antimicrobial agents also
showed higher level of resistance acquired by these strains
compared to the MICs observed during 1995–2000 (5).
The MICs90 of antimicrobial agents tested were as follows:
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Table 1. Isolation frequency of Shigella serotypes from patients admitted to two different hospitals, Kolkata, India 
Place, y, and period of 
sample collection  
No. samples  
tested (n) 
Strains Shigella 
isolated n (%)  S. dysenteriae (n)  S. flexneri  (n)  S. boydii (n)  S. sonnei (n) 
Dr. B.C. Roy Memorial Children’s Hospital 
2001 
Jan–April  
May–Aug 
Sept–Dec 
2002 
Jan–April  
May–Aug 
1,069 
442 
397 
230 
790 
365 
425 
80 (7.5) 
26 (5.9) 
39 (9.8) 
15 (6.5) 
72 (9.1) 
32 (8.7) 
40 (9.4) 
5 
1 
4 
0 
5 
1 
4 
40 
13 
17 
10 
45 
26 
19 
9 
3 
5 
1 
4 
1 
3 
26 
9 
13 
4 
18 
4 
14 
Infectious Diseases Hospital 
2002 
July–Aug  
 
77 
 
27 (35) 
 
24 
 
2 
 
0 
 
1 ampicillin (512 µg/mL), tetracycline (>256 µg/ml), chlo-
ramphenicol (<256 µg/mL), nalidixic acid (>256 µg/mL),
norfloxacin (>32 µg/mL), and ciprofloxacin (>8 µg/mL).
In contrast, other serotypes of shigellae were uniformly
susceptible (100%) to ciprofloxacin and norfloxacin and
showed partial resistance to ampicillin (60%), tetracycline
(94%), cotrimoxazole (98%), and nalidixic acid (45%). 
Initially, physicians advised norfloxacin and cipro-
floxacin for routine treatment of shigellosis; because of poor
clinical responses, subsequent patients were treated with
ofloxacin to which the organism was susceptible (100%).
No case fatality and no case of hemolytic uremic syndrome
have been reported among the present series of patients.
Median time for resolution of symptoms of the patients was
4 days from the date of admission to the hospital.
When S. dysenteriae 1 strains were screened for viru-
lent gene profiles by PCR with published primer sequences
(9), all S. dysenteriae 1 strains (100%) were found to har-
bor stx1 (Shiga toxin), ipaH (invasion plasmid antigen H),
and ial (invasion-associated locus) gene and were negative
for set (Shigella enterotoxin 1) gene. Sixteen (70%) of 23
isolates were positive for sen (Shigella  enterotoxin 2)
gene. Only one S. dysenteriae 1 strain showed both
Shigella enterotoxin 1 and 2 (set and sen) genes. 
Although the proportion of Shigella strains isolated
from case-patients with acute bloody diarrhea increased
(30% to 35%), the rate of S. dysenteriae 1 isolated from Dr.
B.C. Roy Memorial Children’s Hospital (5/237; 2%) was
not as high as that of patients at I.D. Hospital (27/77;
35%). Because I.D. Hospital was a general hospital and
provided treatment to patients of all ages, including chil-
dren, concerned parents of patients who had severe dysen-
tery caused by S. dysenteriae 1 might have brought them
to I.D. Hospital in anticipation that their illness would be
better managed. 
Isolated strains of S. dysenteriae 1 from two recently
documented outbreaks in West Bengal also showed
reduced susceptibility to fluoroquinolones (6,7). In recent
years, the emergence of multidrug-resistant S. dysenteriae
1 strains has also been reported from Southeast Asia and
Africa, although fluoroquinolone resistance was not
observed among the strains (10,11).
While processing the stool samples of patients admitted
to the Children’s Hospital for shigellae species by conven-
tional method, we found a few strains that showed a bio-
chemical reaction typical of Shigella but were nonagglu-
tinable by commercially available antisera. These strains
were positive for ipaH gene when tested by PCR. We des-
ignated those strains as Shigella untypable strains (8). The
strains were sent to the Tokyo Metropolitan Research
Laboratory of Public Health, Tokyo, Japan, for typing, and
they were found to be provisional serovers of Shigella spp.
(Table 2). Table 2 shows the year of isolation and virulent
gene profiles of those strains. All strains were negative for
stx1 gene. They were resistant to chloramphenicol, tetracy-
cline, cotrimoxazole, furazolidone, and amoxicillin. But
all strains were susceptible to nalidixic acid, norfloxacin,
ciprofloxacin, gentamicin, amikacin, and cefotaxime. This
drug-resistance profile contrasted with that of recently
emerged S. dysenteriae type 1 strains. Similar strains have
also been identified in other studies (12–14). To our
knowledge, this is the first report of the isolation and iden-
tification of provisional serovars of S. dysenteriae and S.
boydii from Kolkata, India.
Conclusions
Our study reports increased isolation of shigellae with
reemergence of S. dysenteriae 1 in and around Kolkata,
India. This increase has public health importance with
respect to monitoring impending outbreaks of shigellosis
and implementing appropriate strategies for containment
of this deadly organism.
Emergence of multidrug-resistant Shigella strains is of
concern to clinicians in treating shigellosis cases. Because
the recently emerged S. dysenteriae 1 strain was resistant
(100%) to ampicillin, cotrimoxazole, nalidixic acid, nor-
floxacin, and ciprofloxacin, which were commonly used
for shigellosis cases, ofloxacin is currently recommended
for treatment. A concomitant search for alternate new
drugs should be continued because, although newer
antimicrobial drugs can offer hope for treatment of shigel-
losis, emergence of resistance to the new drugs is also not
far in the future. Therefore, generating an effective vaccine
can offer the ultimate solution to such problems. Perhaps
the more effective way of reducing the impact of the dis-
ease and the risk of contracting infection lies in improving
poor living conditions, disseminating health education,
and supplying safe drinking water. However, accomplish-
ing those objectives and reaching the goal is not an easy
task in developing countries. Laboratory detection capabil-
ities also need to be strengthened at all levels to increase
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Figure. Epidemic curve for Shigella dysenteriae 1 case-patients
admitted to Infectious Diseases, Hospital, Kolkata, India, during
July and August 2002.DISPATCHES
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the baseline surveillance data for improved isolation of the
pathogen. Identifying some strains with provisional
serovars of Shigella spp. for the first time from Kolkata,
India, indicates that all provisionally identified Shigella
strains should be sent to a reference laboratory for typing
and further characterization. 
Studying plasmid profiles of isolated S. dysenteriae 1
strains and typing the strains by using various molecular
tools could provide insight into the origin of these recent-
ly isolated S. dysenteriae 1 strains and the relationships
among the strains. 
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Table 2. Virulence gene profiles of provisional serovars of Shigella spp. isolated from Kolkata, India 
Detection of virulence genes by PCR
a 
Serial no.  New serovars Shigella spp. (n) 
Mo and 
y of isolation  IpaH  ial  set  sen  stx1 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
S. dysenteriae 204/96 
S. boydii E16553 
S. dysenteriae 93-119 
S. dysenteriae 204/96 
S. dysenteriae E-23507 
S. dysenteriae I-9809-93 
S. dysenteriae 204/96 
May 2000 
June 2000 
Oct 2000 
Aug 2001 
Aug 2001 
Dec 2001 
Mar 2002 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
- 
+ 
+ 
+ 
+ 
+ 
- 
+ 
- 
- 
- 
- 
- 
- 
- 
aPCR, polymerase chain reaction; +, positive; -, negative 